T0	Participants 210 306	patients under antihypertensive treatment visit-to-visit (or long-term) variability of clinic BP
T1	Participants 717 862	the hypertensive patients of the European Lacidipine Study on Atherosclerosis (ELSA) trial treated for 4 years with either atenolol or lacidipine
T2	Participants 1306 1313	period.
T3	Participants 1314 1517	Patients in whom at least seven clinic (6-month intervals) or at least three (yearly intervals) 24-h values were available from the end of the drug titration phase to the end of the study were considered
T4	Participants 2302 2345	CONCLUSION In mild-to-moderate hypertensive